Therapeutic antibodies - 1 News by Calypso Biotech

Therapeutic antibodies - 1 News by Calypso Biotech

image description

Calypso Enters into Agreement to Be Acquired by Novartis

09-Jan-2024 - Calypso Biotech BV, a leader in the development of Interleukin15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG. Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development ...

therapeutic antibodies aquisition autoimmune diseases

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 26,968 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now